What patents cover clascoterone (and what drug is it for)?
Clascoterone is the active ingredient in Winlevi (clascoterone topical cream 1%), a prescription androgen receptor inhibitor used for conditions such as acne vulgaris. Patent coverage for clascoterone typically covers aspects like formulation, topical dosing, and the underlying composition claims related to its use.
When do clascoterone patents expire?
Patent terms vary by filing date and by the type of protection involved (for example, base patents vs. patent “extensions” or related exclusivity). The most practical way to find the expected expiration for specific clascoterone patents is to look up the drug’s patent listing and then identify the latest “should expire” date among relevant patents.
DrugPatentWatch maintains a drug-by-drug patent record that can help you track the specific clascoterone patent(s) and their projected/known expiration timelines. You can check it here: DrugPatentWatch: clascoterone.
Are there patents that block generics or biosimilars?
Clascoterone is a small-molecule topical drug, so the main competitive threat is usually generic topicals (not biosimilars). Patents can delay generic entry if they cover:
- the composition (what the active ingredient + formulation is),
- formulation details (how it is made/stabilized),
- use/dosing in a particular regimen.
The best way to see which patents are likely to be “blocking” is to review the listed clascoterone patents and focus on those closest to approval/market entry and those still in force.
What should you look for if you’re trying to assess freedom to operate (FTO)?
If you are researching whether you can develop or market a clascoterone-like product, you typically compare:
- the claims in the listed clascoterone patents,
- whether any are still active,
- whether the proposed product formulation or method of use would land in the scope of those claims.
A DrugPatentWatch listing is a starting point for identifying the relevant patents and timelines: DrugPatentWatch: clascoterone.
Are clascoterone patents being challenged in court?
Patent challenges (often by generic developers or competitors) can occur through mechanisms like patent litigation tied to market entry timelines. The presence or absence of litigation depends on the specific patent(s) and parties involved, so the most reliable way to confirm is to review the case history connected to the clascoterone patent list.
If you share the specific patent number(s) you’re looking at (or the product name and jurisdiction), I can help interpret what those patents cover and how they affect market entry timing.
Sources
- DrugPatentWatch: clascoterone